tag:blogger.com,1999:blog-36634196.post2926461742369673110..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: GSK and Pfizer's HIV Joint Venture: Why It’s a Path ForwardChris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-36634196.post-60627332492498302622009-05-30T12:13:59.539-05:002009-05-30T12:13:59.539-05:00Methinks you are buying the spin from the brass at...Methinks you are buying the spin from the brass at GSK and PFE too much. Heck "Our Path Forward" is a corporate euphemism/cliche inside PFE for Captain K's new strategies. Less stenography and more skepticism is needed from bloggers/journalists.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-36634196.post-75854524717934110622009-05-28T16:33:29.267-05:002009-05-28T16:33:29.267-05:00UK antitrust watchdog to investigate plans for Gla...UK antitrust watchdog to investigate plans for Glaxo, Pfizer joint venture<br /><br />The AP (5/28) reports, "Britain's competition watchdog said Wednesday that it will investigate plans by drugmaker GlaxoSmithKline PLC to pool resources with Pfizer Inc. to create a new company to develop and sell HIV medicines." The investigation will focus on "whether the joint venture can be considered to be a merger that will reduce competition in the UK." The Office of Fair Trading will also "decide whether to refer the case to the Competition Commission regulators, which have the power to block or put limits on the deal." According to Glaxo, the new company "will blend" its "portfolio of HIV drugs now on the market -- some with patents approaching expiration – with" Pfizer's "more robust pipeline of drugs in development." The joint venture is expected to "have a 19 percent market share, ranking it No. 2 behind sales leader Gillead Sciences Inc."Anonymousnoreply@blogger.com